• Haemonetics raised fiscal 2027 reported revenue growth guidance to 8%-11% from 5%-8%.
• Organic revenue growth is now forecast at 6%-9%, up from 4%-7%.
• Adjusted operating margin expansion was lowered to 0-50 basis points year over year from 50-100 basis points.
• Free cash flow conversion is expected to exceed 80%, versus about 80% previously.
• Second-quarter revenue rose 9.3% to $357.8 million; adjusted earnings per share increased 6% to $1.35.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.